ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

NPIL licenses Morvus technology

November 6, 2006 | APPEARED IN VOLUME 84, ISSUE 45

India's Nicholas Piramal India Ltd. has bolstered its drug discovery efforts through two technology-licensing pacts with the U.K.-based research firm Morvus Technology. Under the first agreement, NPIL will use Morvus' gene and protein identification technology to find new drugs to treat diabetes and arthritis. The second pact covers a combination therapy for cancer that uses a cyclin-dependent kinase inhibitor to amplify the effectiveness of anticancer drugs. Morvus will receive up-front and milestone payments, as well as a 2% royalty on products that reach the market.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment